Send to

Choose Destination
Heart. 2018 Mar;104(5):407-415. doi: 10.1136/heartjnl-2017-311652. Epub 2017 Aug 5.

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Author information

Cardiovascular Division, King's College Hospital London, British Heart Foundation Centre of Research Excellence, London, UK.
Department of Cardiovascular Medicine, King's College Hospital, London, UK.
Imperial College Healthcare NHS Trust, London, UK.
Department of Primary Care and Public Health Sciences, King's College London, London, UK.



Clinical drug trials in patients with heart failure and preserved ejection fraction have failed to demonstrate improvements in mortality.


We systematically searched Medline, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCT) assessing pharmacological treatments in patients with heart failure with left ventricular (LV) ejection fraction≥40% from January 1996 to May 2016. The primary efficacy outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, heart failure hospitalisation, exercise capacity (6-min walk distance, exercise duration, VO2 max), quality of life and biomarkers (B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide). Random-effects models were used to estimate pooled relative risks (RR) for the binary outcomes, and weighted mean differences for continuous outcomes, with 95% CI.


We included data from 25 RCTs comprising data for 18101 patients. All-cause mortality was reduced with beta-blocker therapy compared with placebo (RR: 0.78, 95%CI 0.65 to 0.94, p=0.008). There was no effect seen with ACE inhibitors, aldosterone receptor blockers, mineralocorticoid receptor antagonists and other drug classes, compared with placebo. Similar results were observed for cardiovascular mortality. No single drug class reduced heart failure hospitalisation compared with placebo.


The efficacy of treatments in patients with heart failure and an LV ejection fraction≥40% differ depending on the type of therapy, with beta-blockers demonstrating reductions in all-cause and cardiovascular mortality. Further trials are warranted to confirm treatment effects of beta-blockers in this patient group.


diastolic dysfunction; heart failure; meta-analysis; mid-range ejection fraction; preserved ejection fraction; systematic review

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center